Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy

A. Faggioni; C. Corradini; G. Barile; G. Cardi; V. Ciarniello; M. Venenzoni; C. Zompetta; M. Maurizi; G. Paludetti; V. Manzari; A. Gradilone; L. Frati

doi:10.1007/BF00402731

Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy

A. Faggioni, C. Corradini, G. Barile, G. Cardi, V. Ciarniello, M. Venenzoni, C. Zompetta, M. Maurizi, G. Paludetti, V. Manzari, A. Gradilone, L. Frati

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

This paper reports the results of the EBV-specific antibody response in 17 Italian nasopharyngeal carcinoma (NPC) patients, 15 other head and neck tumor patients and 15 normal controls. Nucleic acid hybridization has been performed on the biopsy tissue from 4 of the NPC patients, and EBV-DNA was present in two undifferentiated (WHO 3) tumors, and absent in two samples of the keratinizing (WHO 1) type. EBV serology appears to be specifically related to NPC, more evidently for VCA-IgA and EA-IgG antibodies, and useful as an aid in diagnosis of NPC. However, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period of time (at least 5 years) is needed, and is currently being pursued.

Original language	English
Pages (from-to)	157-160
Number of pages	4
Journal	Journal of Cancer Research and Clinical Oncology
Volume	110
Issue number	2
DOIs	https://doi.org/10.1007/BF00402731
Publication status	Published - Sep 1985

Keywords

Antibodies
Epstein-Barr virus
Nasopharyngeal carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/BF00402731

Cite this

Faggioni, A., Corradini, C., Barile, G., Cardi, G., Ciarniello, V., Venenzoni, M., Zompetta, C., Maurizi, M., Paludetti, G., Manzari, V., Gradilone, A., & Frati, L. (1985). Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy. Journal of Cancer Research and Clinical Oncology, 110(2), 157-160. https://doi.org/10.1007/BF00402731

Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy. / Faggioni, A.; Corradini, C.; Barile, G.; Cardi, G.; Ciarniello, V.; Venenzoni, M.; Zompetta, C.; Maurizi, M.; Paludetti, G.; Manzari, V.; Gradilone, A.; Frati, L.

In: Journal of Cancer Research and Clinical Oncology, Vol. 110, No. 2, 09.1985, p. 157-160.

Research output: Contribution to journal › Article › peer-review

Faggioni, A, Corradini, C, Barile, G, Cardi, G, Ciarniello, V, Venenzoni, M, Zompetta, C, Maurizi, M, Paludetti, G, Manzari, V, Gradilone, A & Frati, L 1985, 'Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy', Journal of Cancer Research and Clinical Oncology, vol. 110, no. 2, pp. 157-160. https://doi.org/10.1007/BF00402731

@article{d1e3a00058ad49f1b0d5dc25d3b1a089,

title = "Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy",

abstract = "This paper reports the results of the EBV-specific antibody response in 17 Italian nasopharyngeal carcinoma (NPC) patients, 15 other head and neck tumor patients and 15 normal controls. Nucleic acid hybridization has been performed on the biopsy tissue from 4 of the NPC patients, and EBV-DNA was present in two undifferentiated (WHO 3) tumors, and absent in two samples of the keratinizing (WHO 1) type. EBV serology appears to be specifically related to NPC, more evidently for VCA-IgA and EA-IgG antibodies, and useful as an aid in diagnosis of NPC. However, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period of time (at least 5 years) is needed, and is currently being pursued.",

keywords = "Antibodies, Epstein-Barr virus, Nasopharyngeal carcinoma",

author = "A. Faggioni and C. Corradini and G. Barile and G. Cardi and V. Ciarniello and M. Venenzoni and C. Zompetta and M. Maurizi and G. Paludetti and V. Manzari and A. Gradilone and L. Frati",

year = "1985",

month = sep,

doi = "10.1007/BF00402731",

language = "English",

volume = "110",

pages = "157--160",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy

AU - Faggioni, A.

AU - Corradini, C.

AU - Barile, G.

AU - Cardi, G.

AU - Ciarniello, V.

AU - Venenzoni, M.

AU - Zompetta, C.

AU - Maurizi, M.

AU - Paludetti, G.

AU - Manzari, V.

AU - Gradilone, A.

AU - Frati, L.

PY - 1985/9

Y1 - 1985/9

N2 - This paper reports the results of the EBV-specific antibody response in 17 Italian nasopharyngeal carcinoma (NPC) patients, 15 other head and neck tumor patients and 15 normal controls. Nucleic acid hybridization has been performed on the biopsy tissue from 4 of the NPC patients, and EBV-DNA was present in two undifferentiated (WHO 3) tumors, and absent in two samples of the keratinizing (WHO 1) type. EBV serology appears to be specifically related to NPC, more evidently for VCA-IgA and EA-IgG antibodies, and useful as an aid in diagnosis of NPC. However, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period of time (at least 5 years) is needed, and is currently being pursued.

AB - This paper reports the results of the EBV-specific antibody response in 17 Italian nasopharyngeal carcinoma (NPC) patients, 15 other head and neck tumor patients and 15 normal controls. Nucleic acid hybridization has been performed on the biopsy tissue from 4 of the NPC patients, and EBV-DNA was present in two undifferentiated (WHO 3) tumors, and absent in two samples of the keratinizing (WHO 1) type. EBV serology appears to be specifically related to NPC, more evidently for VCA-IgA and EA-IgG antibodies, and useful as an aid in diagnosis of NPC. However, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period of time (at least 5 years) is needed, and is currently being pursued.

KW - Antibodies

KW - Epstein-Barr virus

KW - Nasopharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0022239495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022239495&partnerID=8YFLogxK

U2 - 10.1007/BF00402731

DO - 10.1007/BF00402731

M3 - Article

C2 - 2995399

AN - SCOPUS:0022239495

VL - 110

SP - 157

EP - 160

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -

Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this